ClinicalTrials.gg
RecruitingNCT07497321ProGYNiousUpdated Oct 30, 2026

Safety and Performance of a Pelvic Floor Mesh Implant for Laparoscopic Sacrocolpopexy (ProGYNious)

An interventional study of Surgical mesh for pelvic organ prolapse repair (ProGYNious) in Pelvic Organ Prolapse (POP), Synthetic Mesh and Laparoscopic Surgery, sponsored by A.M.I. Agency for Medical Innovations GmbH. Recruiting at 4 sites in 2 countries. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by A.M.I. Agency for Medical Innovations GmbH · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Pelvic Organ Prolapse with a site in Germany — 4 open to participants now, 6 under way, none of them phase 3. Pelvic Organ Prolapse · Germany.

Started
2026
the only one that year
No phase
4 of 19
2 open now
Registered
19th of 19
by date
Lead sponsor
4 of 19
A.M.I. Agency for Medical Innovations GmbH

Among the 19 studies in Pelvic Organ Prolapse with a site in Germany, this one is the only one that started in 2026, is one of 4 with no phase, and was the 19th registered.

Pelvic Organ Prolapse

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

Browse Pelvic Organ Prolapse studies →

Open to participants now

4 of the 19 studies in Pelvic Organ Prolapse with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pelvic Organ Prolapse with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this clinical investigation is to collect clinical data about the ProGYNious Mesh based on a prospective clinical investigation. The primary objective is to verify the treatment outcome and success of the ProGYNious mesh implant in pelvic organ prolapse repair. The secondary objective is to confirm the safety, risks, complications and quality of life of ProGYNious as an implant for pelvic organ prolapse repair.

Read the detailed description

ProGYNious is a Y-shaped synthetic mesh implant which combines two types of polypropylene meshes with different properties. The mesh body is made of ultra-light monofilament polypropylene with a wide hexagonal pore structure with a high level of elasticity. A reinforced mesh material with a smaller pore structure is used for the mesh neck which achieves a strong fixation to the sacral promontory.

This study is a prospective international multi-center post-market clinical investigation with five participating medical centers.

03

Conditions studied

  • Pelvic Organ Prolapse (POP)
  • Synthetic Mesh
  • Laparoscopic Surgery
  • Gynecologic Laparoscopic Surgery
  • Sacrocolpopexy
  • Pelvic Floor Prolapse
  • Pelvic Floor
  • Implant

Browse trials for

Keywords

  • ProGYNious
  • A.M.I.
  • AMI
  • Agency for Medical Innovation
  • Y Mesh
  • Progyn
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a candidate for surgical repair of pelvic organ prolapse by ProGYNious implant according to the indication of the product under evaluation
  • Symptomatic pelvic organ prolapse with POP-Q >= 2
  • Age >18 years and ≤ 80years
  • Subject is willing and able to cooperate with follow-up examinations
  • Subject has been informed of the study procedures and the treatment and has signed an form

Exclusion criteria

Exclusion Criteria:

  • previous or concurrent cancer which may affect the successful treament with laparoscopic mesh
  • known or suspected to ProGYNious mesh or a component of ProGYNious mesh (Polypropylene)
  • known severe osteoporosis
  • pregnancy, suspected pregnancy and breastfeeding
  • bleeding of unknown cause in the genital area
  • previously irradiated patients in the pelvic area
  • drug or medication abuse, medical, psychological or social circumstances that could affect the patient's participation in the study or the evaluation of the study results
  • Any previous interventions with surgical mesh for pelvic organ prolapse and/or urinary incontinence
  • Unable to understand study requirements or is unable to comply with follow-up schedule
  • according to the instruction for use of the device
  • patients with an increased risk of infection or impaired wound healing (e.g. Diabetes mellitus with >10, systemic diseases, etc.)
  • concomitant Sling/TVT procedure
  • lower than follow-up period (e.g. ASA 4)
  • non-symptomatic pelvic organ prolapse
  • chronic pain syndrome
  • chronic respiratory disease (e.g. , chronic cough)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Laparoscopic surgery with a synthetic mesh implant (ProGYNious)

    Implantation of ProGYNious

    Device: Surgical mesh for pelvic organ prolapse repair (ProGYNious)

Interventions

  • DeviceSurgical mesh for pelvic organ prolapse repair (ProGYNious)

    Implantation of a pelvic floor mesh implant for laparoscopic sacrocolpopexy

06

What researchers measure

Primary outcomes

  1. Objective cure rate for pelvic organ prolapse

    Objective cure rate during follow-up defined by: 1. Anatomic cure by POP-Q \<= 1 (Pelvic Organ Prolapse Quantification System) 2. Absence of bulge symptoms 3. No additional pelvic organ prolapse treatment necessary

    Time frame: 3 months and 12 months post-operative

Secondary outcomes

  1. Complications and adverse events during follow-up

    Peri- and post-operative complications, mesh erosion / mesh extrusion (analyzed according to the ICS/IUGA Complication Classification), de novo stress urinary incontinence, de novo urge urinary incontinence

    Time frame: 3 months and 12 months post-operative

  2. Objective outcome (POP-Q)

    Intra-individual comparison of the POP-Q (Pelvic Organ Prolapse Quantification System) locations and antomical markers (pre-operative vs. post-operative). The Pelvic Organ Prolapse Quantification (POP-Q) system is an objective, standardized, site-specific system used by clinicians to assess, describe, and stage pelvic support in women. It uses 6 anatomical points measured in centimeters relative to the hymen to diagnose the severity of prolapse.

    Time frame: 3 months and 12 months post-operative

  3. Quality of Life (QoL) and sexual function

    Analysis of the improvement in quality of life (QoL) and sexual function with the German Pelvic Floor Questionnaire (GPFQ, Deutscher Beckenbodenfragebogen). The GPFQ does contain the domains bladder function, bowel function, prolapse and sexual symptoms. In each domain a total of 10 points may be reached. The maximum symptom score for the entire questionnaire are 40 points.

    Time frame: 3 months and 12 months post-operative

  4. Subjective success

    Subjective success described by Patients Global Impression of Improvement (PGI-I). Patient Global Impression of Improvement (PGI-I) score four years after incontinence surgery. The Patient Global Impression of Improvement (PGI-I) is a global index that may be used to rate the response of a condition to a therapy (transition scale). It is a simple, direct, easy to use scale that is intuitively understandable to clinicians: * Very much better * Much better * A little better * No change * A little worse * Much worse * Very much worse

    Time frame: 3 months and 12 months post-operative

07

Study locations

1 of 4 sites recruiting
  • Universitätsklinikum Wiener Neustadt, Klinik für Gynäkologie und Geburtshilfe
    Wiener Neustadt, Lower Austria 2700, Austria
    Recruiting
    • Balázs Stenczer, MD · Contact
    • Balázs Stenczer, MD · Principal investigator
    • Balint Balogh, MD, MHBA · Sub investigator
  • Universitätsklinikum Erlangen, Frauenklinik
    Erlangen, Bavaria 91054, Germany
    Not yet recruiting
    • Felix Heindl, MD, PD MHBA · Contact
    • Felix Heindl, MD, MHBA · Principal investigator
    • Stephanie Burghaus, MD, MHBA · Sub investigator
  • Klinik Agatharied, Gynäkologie & Geburtshilfe
    Hausham, Bavaria 83734, Germany
    Not yet recruiting
    • Stefan Rimbach, MD, PD Dr. med. Dr. h. c. · Contact
    • Stefan Rimbach, MD, PD Dr. med. Dr. h. c. · Principal investigator
    • Miriam Schempershofe, MD · Sub investigator
  • Universitätsmedizin Frankfurt, Klinik für Gynäkologie und Geburtshilfe
    Frankfurt am Main, Hesse 60596, Germany
    Not yet recruiting
    • Khayal Gasimli, MD, Prof. · Contact
    • Khayal Gasimli, MD, Prof. · Principal investigator
    • Sven Becker, MD, Prof. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

Of 179 interventional studies with no phase under Pelvic Organ Prolapse, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 26 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Apr 2026 → Oct 2026, primary completion Jul 2028 → Dec 2028 and completion Sep 2028 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 27, 2026
StartActual
Oct 28, 2026was Apr 2026
Primary completionEst.
Dec 31, 2028was Jul 2028
CompletionEst.
Mar 31, 2029was Sep 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
1 site removed. 4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
Show 4 sites
  • Universitätsklinikum Wiener Neustadt, Klinik für Gynäkologie und Geburtshilfe · Wiener Neustadt, Austriano status→Recruiting
  • Universitätsklinikum Erlangen, Frauenklinik · Erlangen, Germanyno status→Not yet recruiting
  • Klinik Agatharied, Gynäkologie & Geburtshilfe · Hausham, Germanyno status→Not yet recruiting
  • Universitätsmedizin Frankfurt, Klinik für Gynäkologie und Geburtshilfe · Frankfurt am Main, Germanyno status→Not yet recruiting
Show 1 removed
  • Kardinal Schwarzenberg Klinikum · Schwarzach im Pongau, Austria
Oct 30, 2026
Start date
Apr 15, 2026→Oct 28, 2026 (actual)
Oct 30, 2026
Primary completion
Jul 30, 2028→Dec 31, 2028
Oct 30, 2026
Study completion
Sep 30, 2028→Mar 31, 2029
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    1 site removed. 4 sites changed recruiting status (3 now not yet recruiting, 1 now recruiting)
    Show 4 sites
    • Universitätsklinikum Wiener Neustadt, Klinik für Gynäkologie und Geburtshilfe · Wiener Neustadt, Austriano status→Recruiting
    • Universitätsklinikum Erlangen, Frauenklinik · Erlangen, Germanyno status→Not yet recruiting
    • Klinik Agatharied, Gynäkologie & Geburtshilfe · Hausham, Germanyno status→Not yet recruiting
    • Universitätsmedizin Frankfurt, Klinik für Gynäkologie und Geburtshilfe · Frankfurt am Main, Germanyno status→Not yet recruiting
    Show 1 removed
    • Kardinal Schwarzenberg Klinikum · Schwarzach im Pongau, Austria
    Start date Apr 15, 2026→Oct 28, 2026 (now actual)
    Primary completion Jul 30, 2028→Dec 31, 2028
    Study completion Sep 30, 2028→Mar 31, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07497321
Lead sponsor
A.M.I. Agency for Medical Innovations GmbH
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Oct 28, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Florian Blab, MA
Contact
ca@ami.at
+43 5522 90505-0
Balazs Stenczer, MD
principal investigator · University Hospital Wiener Neustadt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion